Drugs / PROINSULIN HUMAN
PROINSULIN HUMAN
also known as
LY-167005 · Proinsulin · Proinsulin biosynthetic human · Proinsulin recombinant human · Recombinant human proinsulin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT01536431 Comparator | Jan 2012 → Feb 2015 | type 1 diabetes mellitus | Cardiff University | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PROINSULIN HUMAN | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109212 ↗ |
| Known as | LY-167005 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109212 ↗ |
| Known as | Proinsulin | “Phase 1b Study of Proinsulin (PI) Peptide Immunotherapy in New-Onset Type 1 Diabetes” NCT01536431 ↗ |
| Known as | Proinsulin biosynthetic human | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109212 ↗ |
| Known as | Proinsulin recombinant human | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109212 ↗ |
| Known as | Recombinant human proinsulin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109212 ↗ |
| Modality | Peptide | “proinsulin (PI) peptide immunotherapy” NCT01536431 ↗ |